Formulary coverage for lipid-lowering drugs recommended for children

Esther Y. Yoon, Gary L. Freed, Matthew M. Davis, Sarah J. Clark

Research output: Contribution to journalArticlepeer-review


Objective/methods. A cross-sectional assessment to describe availability, coverage, and pediatric labeling status of lipid-lowering drugs offered by 1 private and 1 public insurance plan formularies. Results. Both insurance plans had equal medication availability of bile acid sequestrants (7), statins (10), and cholesterol-absorption blockers (CAB; 1). The private plan had 3 bile acid sequestrants and 3 statins listed as preferred drugs; the CAB was not preferred. In contrast, the public plan had 5 bile acid sequestrants, 7 statins, and the CAB as preferred drugs. For medications with pediatric labeling, the private plan covered 50% as preferred drugs whereas the public plan covered 70% as preferred drugs. Conclusions. If new recommendations of the American Academy of Pediatrics for treatment of dyslipidemia in children were implemented today, children with the public plan would have equal choice but better coverage of lipid-lowering drugs as preferred drugs, including those with FDA approval, compared with children with the private plan.

Original languageEnglish (US)
Pages (from-to)609-613
Number of pages5
JournalClinical pediatrics
Issue number6
StatePublished - Jul 2009


  • Cholesterol
  • Dyslipidemia
  • Formulary
  • Insurance plans
  • Obesity
  • Pediatric labeling

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Formulary coverage for lipid-lowering drugs recommended for children'. Together they form a unique fingerprint.

Cite this